Sign in

    Richard Gill

    Managing Director and Senior Equity Analyst at JPMorgan Chase & Co.

    Richard Gill is a Managing Director and Senior Equity Analyst at JPMorgan Chase & Co., specializing in coverage of the biotechnology and pharmaceutical sectors. He is known for his in-depth analysis of companies such as Amgen, Gilead Sciences, Regeneron Pharmaceuticals, and Vertex Pharmaceuticals, regularly cited for his actionable research and investment recommendations. Over his career, Gill has maintained strong analyst rankings and high success rates, earning recognition for outperforming the benchmark with notable returns on his coverage portfolio. He began his career in equity research in the early 2000s, previously holding research roles at other leading investment banks before joining JPMorgan Chase & Co., and holds several FINRA securities licenses including the Series 7 and Series 63.

    Richard Gill's questions to CROWN CASTLE (CCI) leadership

    Richard Gill's questions to CROWN CASTLE (CCI) leadership • Q1 2025

    Question

    Richard Gill asked if the strong core new leasing was driven by a particular carrier or was broad-based, and requested a sense of the business backlog for the remainder of the year.

    Answer

    Interim CEO Daniel Schlanger responded that the leasing activity was a continuation of recent trends and was broad-based, not attributable to any single carrier. While not commenting on a specific backlog, he expressed comfort that the current activity levels from customers are sufficient to meet the company's full-year guidance.

    Ask Fintool Equity Research AI